Clinical trial
A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT05061420 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Head and Neck Squamous Cell Carcinoma (HNSCC)
- Lead sponsor
- Sanofi
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- October 8, 2021
- Completion date
- November 26, 2024
- Enrollment
- 59 (actual)
- Sites
- 27
Conditions
As the registry lists them; a condition with its own page is linked.